Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Inflammatory bowel disease (IBD), which mainly consists of Crohn's disease and ulcerative colitis, is a chronic and relapsing inflammatory condition of the gastrointestinal tract. The traditional treatment strategies relied on frequent administration of high dosages of medications, including antibiotics, non-steroidal anti-inflammatory drugs, biologics, and immunomodulators, with the goal of reducing inflammation. Some of these medications were effective in alleviating the early-stage inflammatory symptoms, but their long-term efficacies were compromised by the accumulation of toxicities. Recently, nanoparticle (NP)-based drugs have been widely studied for their potential to solve such problems. Various mechanisms/strategies, including size-, charge-, pH-, pressure-, degradation-, ligand-receptor-, and microbiome- dependent drug delivery systems, have been exploited in preclinical studies. A certain number of NP delivery systems have sought to target drugs to the inflamed intestine. Although several NP-based drugs have entered clinical trials for the treatment of IBD, most have failed due to premature drug release, weak targeting ability, and the high immune toxicity of some of the synthetic nanomaterials that have been used to fabricate the NPs. Therefore, there is still a need for rationally designed and stable NP drug delivery system that can specifically target drugs to the disease site, prolong the drug's residence time, and minimize systemic side effects. This review will analyze the current state of the art in NP-mediated drug delivery for IBD treatment. We will focus on topics such as deliverable targets (at the tissue or cellular level) for treating inflammation; the target-homing NP materials that can interact with such targets; and the major administration routes for treating IBD. These discussions will integrate notable trends in the research and development of IBD medications, including multi-responsive NP-mediated delivery and naturally-derived targeting NPs. Finally, current challenges and future directions will be presented in the hopes of advancing the study of NP-mediated strategies for treating IBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ng, S. C., Shi, H. Y., Hamidi, N., Underwood, F. E., Tang, W., Benchimol, E. I., Panaccione, R., Ghosh, S., Wu, J. C. Y., Chan, F. K. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32448-0 · Cited by 6,087
The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic T reg Cell Homeostasis
Smith, P. M., Howitt, M. R., Panikov, N., Michaud, M., Gallini, C. A., Bohlooly-Y, M., Glickman, J. N., & Garrett, W. S. (2013) · Science · doi:10.1126/science.1241165 · Cited by 5,413
The global burden of IBD: from 2015 to 2025
Kaplan, G. G. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.150 · Cited by 2,639
Epidemiology and risk factors for IBD
Ananthakrishnan, A. N. (2015) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2015.34 · Cited by 1,741 · cited 2×
“3,9,10 Recent studies of the human microbiome revealed that dysbiosis (an alteration of the regular composition of the microbiota) also plays a pivotal role in the development of IBD, 3,11 – 13 adding another layer of complexity of the etiology of this important disease.”
Plant-derived exosomal MicroRNAs shape the gut microbiota
Teng, Y., Ren, Y., Sayed, M., Hu, X., Lei, C., Kumar, A., Hutchins, E., Mu, J., Deng, Z., Luo, C., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2018.10.001 · Cited by 1,027
Dietary gut microbial metabolites, short-chain fatty acids, and host metabolic regulation
Kasubuchi, M., Hasegawa, S., Hiramatsu, T., Ichimura, A., & Kimura, I. (2015) · Nutrients · doi:10.3390/nu7042839 · Cited by 904
Khan, I., Ullah, N., Zha, L., Bai, Y., Khan, A., Zhao, T., Che, T., & Zhang, C. (2019) · Pathogens · doi:10.3390/pathogens8030126 · Cited by 771 · cited 3×
“75,77 In general, IBD patients show an overall decrease in microbial diversity and a reduction of about 25% in microbial genes.”
Pellegrini, C., Antonioli, L., Colucci, R., Blandizzi, C., & Fornai, M. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1856-5 · Cited by 270 · cited 1×
“48,49 The innate immune system comprises a variety of cells, including dendritic cells (DCs), granulocytes (such as neutrophils), macrophages, and monocytes.”
Eniola, A. O., & Hammer, D. A. (2005) · Biomaterials · doi:10.1016/j.biomaterials.2004.03.003 · Cited by 72 · cited 1×
“63,64 Although these innovative approaches have shown excellent delivery ef fi ciency both in vitro and in vivo, additional work is needed to evaluate their toxicity and therapeutic potential in IBD and further improve their targeting speci fi city.”
Hammer, T., Lophaven, S. N., Nielsen, K. R., Petersen, M. S., Munkholm, P., Weihe, P., Burisch, J., & Lynge, E. (2019) · United European Gastroenterology Journal · doi:10.1177/2050640619852244 · Cited by 34 · cited 1×
“3,9,10 Recent studies of the human microbiome revealed that dysbiosis (an alteration of the regular composition of the microbiota) also plays a pivotal role in the development of IBD, 3,11 – 13 adding another layer of complexity of the etiology of this important disease.”
Cited by
Zhang, M., Ma, Y., Ye, X., Zhang, N., Pan, L., & Wang, B. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01464-x · Cited by 522
Liu, C., Yan, X., Zhang, Y., Yang, M., Ma, Y., Zhang, Y., Xu, Q., Tu, K., & Zhang, M. (2022) · Journal of Nanobiotechnology · doi:10.1186/s12951-022-01421-w · Cited by 285
Advances in colon-targeted nano-drug delivery systems: challenges and solutions
Naeem, M., Awan, U. A., Subhan, F., Cao, J., Hlaing, S. P., Lee, J., Im, E., Jung, Y., & Yoo, J.-W. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01219-0 · Cited by 248
Alzahrani, F. A., Khan, M. I., Kameli, N., Alsahafi, E., & Riza, Y. M. (2023) · Biomolecules · doi:10.3390/biom13050839 · Cited by 143
“However, these drugs can be toxic if used for a long time and may not be effective in the long run [72].”
Background
Metadata
- Authors
- Yang, C., & Merlin, D.
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2019-11
- Volume
- Volume 14
- Pages
- 8875-8889
- ISSN
- 1176-9114 (ISSN-L)
- 1178-2013
- OpenAlex
- W2988352267
- Cited by
- 192
- References
- 10
- FWCI
- 7.86
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives. https://app.cochat.ai/papers/10.2147/ijn.s210315
- The paper
- Yang, C., & Merlin, D. (2019). Nanoparticle-Mediated Drug Delivery Systems For The Treatment Of IBD: Current Perspectives. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s210315
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.